2 No-Brainer Biotech Stocks to Buy Right Now
Following the market's gloomy 2022, this year has been a breath of fresh air with the S 500 rising 14% so far in 2023. Some biotech stocks have soared even higher thanks to strong products. Cystic fibrosis specialist Vertex Pharmaceuticals (NASDAQ: VRTX) has risen 19% in 2023, while cancer specialist (NASDAQ: EXEL) has gained 31% -- and both medical areas are likely to see strong demand for a long time to come.
Let's see why these two stocks could make good additions to investors' portfolios now.
Source Fool.com
Exelixis Inc. Stock
With 20 Buy predictions and not the single Sell prediction the community is currently very high on Exelixis Inc..
With a target price of 26 € there is a slightly positive potential of 17.49% for Exelixis Inc. compared to the current price of 22.13 €.